Stay updated on Pediatric Immunotherapy Clinical Trial

Sign up to get notified when there's something new on the Pediatric Immunotherapy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pediatric Immunotherapy Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    Change Detected
    Summary
    The study has expanded to include 14 locations, and the revision has been updated from v2.9.7 to v2.10.0.
    Difference
    0.2%
    Check dated 2024-07-23T14:21:49.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.0%
    Check dated 2024-07-16T06:33:18.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the version of the content on the webpage.
    Difference
    0.0%
    Check dated 2024-07-02T13:17:41.000Z thumbnail image
  8. Check
    30 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent change in the webpage content.
    Difference
    0.0%
    Check dated 2024-06-27T09:41:51.000Z thumbnail image
  9. Check
    31 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent change in the webpage content.
    Difference
    0.0%
    Check dated 2024-06-26T08:34:31.000Z thumbnail image
  10. Check
    32 days ago
    Change Detected
    Summary
    The value 'Show more Show more Revision: v2.9.0' has been updated to 'Show less Drug Information available for: Nivolumab FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : N/A Interventional Model : Single Group Assignment Interventional Model Description: Phase I: To determine the recommended phase II dose (RP2D) of the combination treatment with nivolumab and entinostat administered to adolescents 12-21 years with progressive, relapsed, refractory high-risk solid tumors and CNS tumors To determine the recommended phase II dose (RP2D) of the combination treatment with nivolumab and entinostat administered to children 6-11 years with progressive, relapsed, refractory high-risk solid tumors and CNS Tumors Phase II: To evaluate activity and safety of the combination treatment with nivolumab and entinostat in children and adolescents aged 2-21 years with refractory/relapsed/progressive high-risk solid tumors and CNS tumors with: Group A: a high mutational load (> 100 somatic SNVs/exome), Group C: Focal MYC(N) amplification or ATRT-MYC subgroup, Group E: high TILs or TLS positive (> 600 cells/mm² or presence of TLS). Show less Masking : None (Open Label) Arms and Interventions Participant Group/Arm Intervention/Treatment Experimental : Nivolumab and Entinostat Combination Study of Nivolumab and Entinostat Drug : Nivolumab and Entinostat Patients entering phase I will receive one week entinostat without nivolumab (priming phase) before receiving the combination treatment of nivolumab and entinostat.
    Difference
    42%
    Check dated 2024-06-25T08:06:58.000Z thumbnail image

Stay in the know with updates to Pediatric Immunotherapy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pediatric Immunotherapy Clinical Trial page.